{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:14:10Z","timestamp":1794014050422,"version":"4.8.0"},"reference-count":173,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,7,15]],"date-time":"2014-07-15T00:00:00Z","timestamp":1405382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,7,15]],"date-time":"2014-07-15T00:00:00Z","timestamp":1405382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1038\/nrneurol.2014.121","type":"journal-article","created":{"date-parts":[[2014,7,16]],"date-time":"2014-07-16T03:49:48Z","timestamp":1405482588000},"page":"469-482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":966,"title":["Guillain\u2013Barr\u00e9 syndrome: pathogenesis, diagnosis, treatment and prognosis"],"prefix":"10.1038","volume":"10","author":[{"given":"Bianca","family":"van den Berg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Walgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Drenthen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiaan","family":"Fokke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart C.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter A.","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,15]]},"reference":[{"key":"BFnrneurol2014121_CR1","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/S0140-6736(05)67665-9","volume":"366","author":"RA Hughes","year":"2005","unstructured":"Hughes, R. A. & Cornblath, D. R. Guillain\u2013Barr\u00e9 syndrome. Lancet 366, 1653\u20131666 (2005).","journal-title":"Lancet"},{"key":"BFnrneurol2014121_CR2","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(08)70215-1","volume":"7","author":"PA van Doorn","year":"2008","unstructured":"van Doorn, P. A., Ruts, L. & Jacobs, B. C. Clinical features, pathogenesis, and treatment of Guillain\u2013Barr\u00e9 syndrome. Lancet Neurol. 7, 939\u2013950 (2008).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2014121_CR3","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMra1114525","volume":"366","author":"N Yuki","year":"2012","unstructured":"Yuki, N. & Hartung, H. P. Guillain\u2013Barr\u00e9 syndrome. N. Engl. J. Med. 366, 2294\u20132304 (2012).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl.","key":"BFnrneurol2014121_CR4","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1002\/ana.410270707","volume":"27","author":"AK Asbury","year":"1990","unstructured":"Asbury, A. K. & Cornblath, D. R. Assessment of current diagnostic criteria for Guillain\u2013Barr\u00e9 syndrome. Ann. Neurol. 27 (Suppl.), S21\u2013S24 (1990).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2014121_CR5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/brain\/118.3.577","volume":"118","author":"JW Griffin","year":"1995","unstructured":"Griffin, J. W.  et al. Guillain\u2013Barr\u00e9 syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases. Brain 118, 577\u2013595 (1995).","journal-title":"Brain"},{"key":"BFnrneurol2014121_CR6","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/ana.410440512","volume":"44","author":"RD Hadden","year":"1998","unstructured":"Hadden, R. D.  et al. Electrophysiological classification of Guillain\u2013Barr\u00e9 syndrome: clinical associations and outcome. Plasma Exchange\/Sandoglobulin Guillain\u2013Barr\u00e9 Syndrome Trial Group. Ann. Neurol. 44, 780\u2013788 (1998).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2014121_CR7","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/S1474-4422(13)70215-1","volume":"12","author":"S Kuwabara","year":"2013","unstructured":"Kuwabara, S. & Yuki, N. Axonal Guillain\u2013Barr\u00e9 syndrome: concepts and controversies. Lancet Neurol. 12, 1180\u20131188 (2013).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2014121_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1159\/000052111","volume":"45","author":"FG Van der Mech\u00e9","year":"2001","unstructured":"Van der Mech\u00e9, F. G., Van Doorn, P. A., Meulstee, J., Jennekens, F. G. & GBS-consensus group of the Dutch Neuromuscular Research Support Centre. Diagnostic and classification criteria for the Guillain\u2013Barr\u00e9 syndrome. Eur. Neurol. 45, 133\u2013139 (2001).","journal-title":"Eur. Neurol."},{"key":"BFnrneurol2014121_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11940-010-0103-8","volume":"13","author":"M Mori","year":"2011","unstructured":"Mori, M. & Kuwabara, S. Fisher syndrome. Curr. Treat. Options Neurol. 13, 71\u201378 (2011).","journal-title":"Curr. Treat. Options Neurol."},{"key":"BFnrneurol2014121_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1586\/ern.11.182","volume":"12","author":"M Mori","year":"2012","unstructured":"Mori, M., Kuwabara, S. & Yuki, N. Fisher syndrome: clinical features, immunopathogenesis and management. Expert Rev. Neurother. 12, 39\u201351 (2012).","journal-title":"Expert Rev. Neurother."},{"key":"BFnrneurol2014121_CR11","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1093\/brain\/awm004","volume":"130","author":"RA Hughes","year":"2007","unstructured":"Hughes, R. A.  et al. Immunotherapy for Guillain\u2013Barr\u00e9 syndrome: a systematic review. Brain 130, 2245\u20132257 (2007).","journal-title":"Brain"},{"key":"BFnrneurol2014121_CR12","doi-asserted-by":"publisher","unstructured":"Hughes, R. A., Swan A. V. & van Doorn, P. A. Intravenous immunoglobulin for Guillain\u2013Barr\u00e9 syndrome. Cochrane Database of Systematic Reviews, Issue 12. Art. No.: CD002063. http:\/\/dx.doi.org\/10.1002\/14651858.CD002063.pub5.","DOI":"10.1002\/14651858.CD002063.pub5"},{"key":"BFnrneurol2014121_CR13","doi-asserted-by":"publisher","unstructured":"Raphael, J. C., Chevret, S., Hughes, R. A. & Annane, D. Plasma exchange for Guillain\u2013Barr\u00e9 syndrome. Cochrane Database of Systematic Reviews, Issue 7. Art. No.: CD001798. http:\/\/dx.doi.org\/10.1002\/14651858.CD001798.pub2.","DOI":"10.1002\/14651858.CD001798.pub2"},{"key":"BFnrneurol2014121_CR14","doi-asserted-by":"publisher","unstructured":"Hughes, R. A., Pritchard, J. & Hadden, R. D. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain\u2013Barr\u00e9 syndrome. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD008630. http:\/\/dx.doi.org\/10.1002\/14651858.CD008630.pub3.","DOI":"10.1002\/14651858.CD008630.pub3"},{"key":"BFnrneurol2014121_CR15","doi-asserted-by":"publisher","unstructured":"Hughes, R. A. & van Doorn, P. A. Corticosteroids for Guillain\u2013Barr\u00e9 syndrome. Cochrane Database of Systematic Reviews, Issue 8. Art. No.: CD001446. http:\/\/dx.doi.org\/10.1002\/14651858.CD001446.pub4.","DOI":"10.1002\/14651858.CD001446.pub4"},{"key":"BFnrneurol2014121_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000324710","volume":"36","author":"JJ Sejvar","year":"2011","unstructured":"Sejvar, J. J., Baughman, A. L., Wise, M. & Morgan, O. W. Population incidence of Guillain\u2013Barr\u00e9 syndrome: a systematic review and meta-analysis. Neuroepidemiology 36, 123\u2013133 (2011).","journal-title":"Neuroepidemiology"},{"key":"BFnrneurol2014121_CR17","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3201\/eid1707.101999","volume":"17","author":"Z Islam","year":"2011","unstructured":"Islam, Z.  et al. High incidence of Guillain\u2013Barr\u00e9 syndrome in children, Bangladesh. Emerg. Infect. Dis. 17, 1317\u20131318 (2011).","journal-title":"Emerg. Infect. Dis."},{"key":"BFnrneurol2014121_CR18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1159\/000184748","volume":"32","author":"A McGrogan","year":"2009","unstructured":"McGrogan, A., Madle, G. C., Seaman, H. E. & de Vries, C. S. The epidemiology of Guillain\u2013Barr\u00e9 syndrome worldwide. A systematic literature review. Neuroepidemiology 32, 150\u2013163 (2009).","journal-title":"Neuroepidemiology"},{"key":"BFnrneurol2014121_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1590\/S0004-282X2004000100006","volume":"62","author":"MS Rocha","year":"2004","unstructured":"Rocha, M. S., Brucki, S. M., Carvalho, A. A. & Lima, U. W. Epidemiologic features of Guillain\u2013Barr\u00e9 syndrome in S\u00e3o Paulo, Brazil. Arq. Neuropsiquiatr. 62, 33\u201337 (2004).","journal-title":"Arq. Neuropsiquiatr."},{"key":"BFnrneurol2014121_CR20","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1212\/WNL.56.11.1467","volume":"56","author":"R van Koningsveld","year":"2001","unstructured":"van Koningsveld, R.  et al. Gastroenteritis-associated Guillain\u2013Barr\u00e9 syndrome on the Caribbean island Cura\u00e7ao. Neurology 56, 1467\u20131472 (2001).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR21","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/0140-6736(91)90606-P","volume":"338","author":"GM McKhann","year":"1991","unstructured":"McKhann, G. M.  et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet 338, 593\u2013597 (1991).","journal-title":"Lancet"},{"key":"BFnrneurol2014121_CR22","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1136\/jnnp.2004.051136","volume":"76","author":"A Hiraga","year":"2005","unstructured":"Hiraga, A.  et al. Recovery patterns and long term prognosis for axonal Guillain\u2013Barr\u00e9 syndrome. J. Neurol. Neurosurg. Psychiatry 76, 719\u2013722 (2005).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2014121_CR23","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/brain\/118.3.597","volume":"118","author":"TW Ho","year":"1995","unstructured":"Ho, T. W.  et al. Guillain\u2013Barr\u00e9 syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 118, 597\u2013605 (1995).","journal-title":"Brain"},{"key":"BFnrneurol2014121_CR24","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1212\/WNL.0b013e3181cff735","volume":"74","author":"Z Islam","year":"2010","unstructured":"Islam, Z.  et al. Axonal variant of Guillain\u2013Barr\u00e9 syndrome associated with Campylobacter infection in Bangladesh. Neurology 74, 581\u2013587 (2010).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR25","doi-asserted-by":"publisher","first-page":"4211","DOI":"10.4049\/jimmunol.177.6.4211","volume":"177","author":"K Geleijns","year":"2006","unstructured":"Geleijns, K.  et al. Mannose-binding lectin contributes to the severity of Guillain\u2013Barr\u00e9 syndrome. J. Immunol. 177, 4211\u20134217 (2006).","journal-title":"J. Immunol."},{"key":"BFnrneurol2014121_CR26","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jneuroim.2012.03.006","volume":"246","author":"D Sang","year":"2012","unstructured":"Sang, D.  et al. Fc receptor like 3 in Chinese patients of Han nationality with Guillain\u2013Barr\u00e9 syndrome. J. Neuroimmunol. 246, 65\u201368 (2012).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol2014121_CR27","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1212\/WNL.51.4.1110","volume":"51","author":"BC Jacobs","year":"1998","unstructured":"Jacobs, B. C.  et al. The spectrum of antecedent infections in Guillain\u2013Barr\u00e9 syndrome: a case\u2013control study. Neurology 51, 1110\u20131115 (1998).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR28","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1212\/WNL.56.6.758","volume":"56","author":"RD Hadden","year":"2001","unstructured":"Hadden, R. D.  et al. Preceding infections, immune factors, and outcome in Guillain\u2013Barr\u00e9 syndrome. Neurology 56, 758\u2013765 (2001).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR29","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1212\/WNL.0000000000000111","volume":"82","author":"B van den Berg","year":"2014","unstructured":"van den Berg, B.  et al. Guillain\u2013Barr\u00e9 syndrome associated with preceding hepatitis E virus infection. Neurology 82, 491\u2013497 (2014).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR30","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1093\/cid\/cit512","volume":"57","author":"CH Geurtsvankessel","year":"2013","unstructured":"Geurtsvankessel, C. H.  et al. Hepatitis E and Guillain\u2013Barr\u00e9 syndrome. Clin. Infect. Dis. 57, 1369\u20131370 (2013).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrneurol2014121_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1086\/504294","volume":"194","author":"CC Tam","year":"2006","unstructured":"Tam, C. C.  et al. Incidence of Guillain\u2013Barr\u00e9 syndrome among patients with Campylobacter infection: a general practice research database study. J. Infect. Dis. 194, 95\u201397 (2006).","journal-title":"J. Infect. Dis."},{"key":"BFnrneurol2014121_CR32","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1128\/CMR.11.3.555","volume":"11","author":"I Nachamkin","year":"1998","unstructured":"Nachamkin, I., Allos, B. M. & Ho, T. Campylobacter species and Guillain\u2013Barr\u00e9 syndrome. Clin. Microbiol. Rev. 11, 555\u2013567 (1998).","journal-title":"Clin. Microbiol. Rev."},{"key":"BFnrneurol2014121_CR33","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1017\/S0950268813001908","volume":"142","author":"BR Jackson","year":"2014","unstructured":"Jackson, B. R.  et al. Binational outbreak of Guillain\u2013Barr\u00e9 syndrome associated with Campylobacter jejuni infection, Mexico and USA, 2011. Epidemiol. Infect. 142, 1089\u20131099 (2014).","journal-title":"Epidemiol. Infect."},{"key":"BFnrneurol2014121_CR34","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1128\/IAI.70.3.1202-1208.2002","volume":"70","author":"CW Ang","year":"2002","unstructured":"Ang, C. W.  et al. Structure of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity and clinical features of Guillain\u2013Barr\u00e9 and Miller Fisher patients. Infect. Immun. 70, 1202\u20131208 (2002).","journal-title":"Infect. Immun."},{"key":"BFnrneurol2014121_CR35","doi-asserted-by":"publisher","first-page":"748","DOI":"10.4049\/jimmunol.0903014","volume":"185","author":"ML Kuijf","year":"2010","unstructured":"Kuijf, M. L.  et al. TLR4-mediated sensing of Campylobacter jejuni by dendritic cells is determined by sialylation. J. Immunol. 185, 748\u2013755 (2010).","journal-title":"J. Immunol."},{"key":"BFnrneurol2014121_CR36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0165-5728(00)00369-6","volume":"111","author":"CW Ang","year":"2000","unstructured":"Ang, C. W.  et al. A case of Guillain\u2013Barr\u00e9 syndrome following a family outbreak of Campylobacter jejuni enteritis. J. Neuroimmunol. 111, 229\u2013233 (2000).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol2014121_CR37","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1093\/brain\/awf272","volume":"125","author":"HJ Willison","year":"2002","unstructured":"Willison, H. J. & Yuki, N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 125, 2591\u20132625 (2002).","journal-title":"Brain"},{"key":"BFnrneurol2014121_CR38","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jneuroim.2010.02.001","volume":"223","author":"K Kaida","year":"2010","unstructured":"Kaida, K. & Kusunoki, S. Antibodies to gangliosides and ganglioside complexes in Guillain\u2013Barr\u00e9 syndrome and Fisher syndrome: mini-review. J. Neuroimmunol. 223, 5\u201312 (2010).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol2014121_CR39","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2183\/pjab.88.299","volume":"88","author":"N Yuki","year":"2012","unstructured":"Yuki, N. Guillain\u2013Barr\u00e9 syndrome and anti-ganglioside antibodies: a clinician\u2013scientist's journey. Proc. Jpn Acad. Ser. B Phys. Biol. Sci. 88, 299\u2013326 (2012).","journal-title":"Proc. Jpn Acad. Ser. B Phys. Biol. Sci."},{"key":"BFnrneurol2014121_CR40","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1074\/jbc.M108452200","volume":"277","author":"M Gilbert","year":"2002","unstructured":"Gilbert, M.  et al. The genetic bases for the variation in the lipo-oligosaccharide of the mucosal pathogen, Campylobacter jejuni. Biosynthesis of sialylated ganglioside mimics in the core oligosaccharide. J. Biol. Chem. 277, 327\u2013337 (2002).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol2014121_CR41","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/89831","volume":"7","author":"A van Belkum","year":"2001","unstructured":"van Belkum, A.  et al. A Campylobacter jejuni gene associated with immune-mediated neuropathy. Nat. Med. 7, 752\u2013753 (2001).","journal-title":"Nat. Med."},{"key":"BFnrneurol2014121_CR42","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1128\/IAI.00872-06","volume":"75","author":"PC Godschalk","year":"2007","unstructured":"Godschalk, P. C.  et al. Structural characterization of Campylobacter jejuni lipooligosaccharide outer cores associated with Guillain\u2013Barr\u00e9 and Miller Fisher syndromes. Infect. Immun. 75, 1245\u20131254 (2007).","journal-title":"Infect. Immun."},{"key":"BFnrneurol2014121_CR43","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.bbagen.2007.10.001","volume":"1780","author":"S Kusunoki","year":"2008","unstructured":"Kusunoki, S., Kaida, K. & Ueda, M. Antibodies against gangliosides and ganglioside complexes in Guillain\u2013Barr\u00e9 syndrome: new aspects of research. Biochim. Biophys. Acta 1780, 441\u2013444 (2008).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnrneurol2014121_CR44","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1136\/jnnp.2010.226639","volume":"82","author":"J Drenthen","year":"2011","unstructured":"Drenthen, J.  et al. Guillain\u2013Barr\u00e9 syndrome subtypes related to Campylobacter infection. J. Neurol. Neurosurg. Psychiatry 82, 300\u2013305 (2011).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2014121_CR45","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/1531-8249(200010)48:4<624::AID-ANA9>3.0.CO;2-O","volume":"48","author":"K Ogawara","year":"2000","unstructured":"Ogawara, K.  et al. Axonal Guillain\u2013Barr\u00e9 syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann. Neurol. 48, 624\u2013631 (2000).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2014121_CR46","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/brain\/118.4.841","volume":"118","author":"LH Visser","year":"1995","unstructured":"Visser, L. H.  et al. Guillain\u2013Barr\u00e9 syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain\u2013Barr\u00e9 Study Group. Brain 118, 841\u2013847 (1995).","journal-title":"Brain"},{"key":"BFnrneurol2014121_CR47","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S0022-510X(99)00056-8","volume":"164","author":"N Yuki","year":"1999","unstructured":"Yuki, N.  et al. Autoantibodies to GM1b and GalNAc-GD1a: relationship to Campylobacter jejuni infection and acute motor axonal neuropathy in China. J. Neurol. Sci. 164, 134\u2013138 (1999).","journal-title":"J. Neurol. Sci."},{"key":"BFnrneurol2014121_CR48","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/ana.410310619","volume":"31","author":"A Chiba","year":"1992","unstructured":"Chiba, A., Kusunoki, S., Shimizu, T. & Kanazawa, I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann. Neurol. 31, 677\u2013679 (1992).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2014121_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2009.05.020","volume":"215","author":"N Yuki","year":"2009","unstructured":"Yuki, N. Fisher syndrome and Bickerstaff brainstem encephalitis (Fisher\u2013Bickerstaff syndrome). J. Neuroimmunol. 215, 1\u20139 (2009).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol2014121_CR50","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1136\/jnnp.62.6.641","volume":"62","author":"BC Jacobs","year":"1997","unstructured":"Jacobs, B. C., van Doorn, P. A., Groeneveld, J. H., Tio-Gillen A. P. & van der Mech\u00e9, F. G. Cytomegalovirus infections and anti-GM2 antibodies in Guillain\u2013Barr\u00e9 syndrome. J. Neurol. Neurosurg. Psychiatry 62, 641\u2013643 (1997).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2014121_CR51","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/ana.20222","volume":"56","author":"K Kaida","year":"2004","unstructured":"Kaida, K.  et al. Ganglioside complexes as new target antigens in Guillain\u2013Barr\u00e9 syndrome. Ann. Neurol. 56, 567\u2013571 (2004).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2014121_CR52","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/jns5.12020","volume":"18","author":"S Rinaldi","year":"2013","unstructured":"Rinaldi, S. Update on Guillain\u2013Barr\u00e9 syndrome. J. Peripher. Nerv. Syst. 18, 99\u2013112 (2013).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"BFnrneurol2014121_CR53","doi-asserted-by":"publisher","first-page":"e82337","DOI":"10.1371\/journal.pone.0082337","volume":"8","author":"S Rinaldi","year":"2013","unstructured":"Rinaldi, S.  et al. Antibodies to heteromeric glycolipid complexes in Guillain\u2013Barr\u00e9 syndrome. PLoS ONE 8, e82337 (2013).","journal-title":"PLoS ONE"},{"key":"BFnrneurol2014121_CR54","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1073\/pnas.012540899","volume":"99","author":"SI Hakomori","year":"2002","unstructured":"Hakomori, S. I. The glycosynapse. Proc. Natl Acad. Sci. USA 99, 225\u2013232 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2014121_CR55","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jneuroim.2007.05.014","volume":"188","author":"ML Kuijf","year":"2007","unstructured":"Kuijf, M. L.  et al. Origin of ganglioside complex antibodies in Guillain\u2013Barr\u00e9 syndrome. J. Neuroimmunol. 188, 69\u201373 (2007).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol2014121_CR56","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/ana.410400414","volume":"40","author":"C Hafer-Macko","year":"1996","unstructured":"Hafer-Macko, C.  et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann. Neurol. 40, 635\u2013644 (1996).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2014121_CR57","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1085-9489.2005.0010202.x","volume":"10","author":"HJ Willison","year":"2005","unstructured":"Willison, H. J. The immunobiology of Guillain\u2013Barr\u00e9 syndromes. J. Peripher. Nerv. Syst. 10, 94\u2013112 (2005).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"BFnrneurol2014121_CR58","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1093\/brain\/awq119","volume":"133","author":"R McGonigal","year":"2010","unstructured":"McGonigal, R.  et al. Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. Brain 133, 1944\u20131960 (2010).","journal-title":"Brain"},{"key":"BFnrneurol2014121_CR59","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1523\/JNEUROSCI.4401-06.2007","volume":"27","author":"K Susuki","year":"2007","unstructured":"Susuki, K.  et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J. Neurosci. 27, 3956\u20133967 (2007).","journal-title":"J. Neurosci."},{"key":"BFnrneurol2014121_CR60","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.expneurol.2011.11.039","volume":"233","author":"K Susuki","year":"2012","unstructured":"Susuki, K.  et al. Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies. Exp. Neurol. 233, 534\u2013542 (2012).","journal-title":"Exp. Neurol."},{"key":"BFnrneurol2014121_CR61","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/brain\/awm316","volume":"131","author":"SK Halstead","year":"2008","unstructured":"Halstead, S. K.  et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 131, 1197\u20131208 (2008).","journal-title":"Brain"},{"key":"BFnrneurol2014121_CR62","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.2008.156463","volume":"80","author":"K Kuitwaard","year":"2009","unstructured":"Kuitwaard, K., van Koningsveld, R., Ruts, L., Jacobs, B. C. & van Doorn, P. A. Recurrent Guillain\u2013Barr\u00e9 syndrome. J. Neurol. Neurosurg. Psychiatry 80, 56\u201359 (2009).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2014121_CR63","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.4049\/jimmunol.1301536","volume":"191","author":"R Huizinga","year":"2013","unstructured":"Huizinga, R.  et al. Sialylation of Campylobacter jejuni endotoxin promotes dendritic cell-mediated B cell responses through CD14-dependent production of IFN-\u03b2 and TNF-\u03b1. J. Immunol. 191, 5636\u20135645 (2013).","journal-title":"J. Immunol."},{"key":"BFnrneurol2014121_CR64","doi-asserted-by":"publisher","first-page":"E106","DOI":"10.1111\/1469-0691.12073","volume":"19","author":"AP Heikema","year":"2013","unstructured":"Heikema, A. P.  et al. Siglec-7 specifically recognizes Campylobacter jejuni strains associated with oculomotor weakness in Guillain\u2013Barr\u00e9 syndrome and Miller Fisher syndrome. Clin. Microbiol. Infect. 19, E106\u2013E112 (2013).","journal-title":"Clin. Microbiol. Infect."},{"key":"BFnrneurol2014121_CR65","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jneuroim.2011.12.003","volume":"243","author":"LY Wu","year":"2012","unstructured":"Wu, L. Y., Zhou, Y., Qin, C. & Hu, B. L. The effect of TNF-\u03b1, Fc\u03b3R and CD1 polymorphisms on Guillain\u2013Barr\u00e9 syndrome risk: evidences from a meta-analysis. J. Neuroimmunol. 243, 18\u201324 (2012).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol2014121_CR66","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","volume":"110","author":"LB Schonberger","year":"1979","unstructured":"Schonberger, L. B.  et al. Guillain\u2013Barr\u00e9 syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977. Am. J. Epidemiol. 110, 105\u2013123 (1979).","journal-title":"Am. J. Epidemiol."},{"key":"BFnrneurol2014121_CR67","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/S0140-6736(12)62189-8","volume":"381","author":"DA Salmon","year":"2013","unstructured":"Salmon, D. A.  et al. Association between Guillain\u2013Barr\u00e9 syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet 381, 1461\u20131468 (2013).","journal-title":"Lancet"},{"key":"BFnrneurol2014121_CR68","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.1016\/j.vaccine.2012.06.093","volume":"30","author":"GA Poland","year":"2012","unstructured":"Poland, G. A., Jacobsen, S. J. Influenza vaccine, Guillain\u2013Barr\u00e9 syndrome, and chasing zero. Vaccine 30, 5801\u20135803 (2012).","journal-title":"Vaccine"},{"key":"BFnrneurol2014121_CR69","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/j.1529-8027.2009.00243.x","volume":"14","author":"K Kuitwaard","year":"2009","unstructured":"Kuitwaard, K., Bos-Eyssen, M. E., Blomkwist-Markens, P. H. & van Doorn, P. A. Recurrences, vaccinations and long-term symptoms in GBS and CIDP. J. Peripher. Nerv. Syst. 14, 310\u2013315 (2009).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"BFnrneurol2014121_CR70","unstructured":"Vereniging Spierziekten Nederland, Nederlandse Vereniging voor Neurologie, Nederlandse Vereniging van Revalidatieartsen. Multidisciplinaire richtlijn Guillain\u2013Barr\u00e9 syndroom [online]. (2010)."},{"issue":"Suppl.","key":"BFnrneurol2014121_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ana.410090703","volume":"9","author":"AK Asbury","year":"1981","unstructured":"Asbury, A. K. Diagnostic considerations in Guillain\u2013Barr\u00e9 syndrome. Ann. Neurol. 9 (Suppl.), 1\u20135 (1981).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2014121_CR72","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","volume":"29","author":"JJ Sejvar","year":"2011","unstructured":"Sejvar, J. J.  et al. Guillain\u2013Barr\u00e9 syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 29, 599\u2013612 (2011).","journal-title":"Vaccine"},{"key":"BFnrneurol2014121_CR73","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/brain\/awt285","volume":"137","author":"C Fokke","year":"2014","unstructured":"Fokke, C.  et al. Diagnosis of Guillain\u2013Barr\u00e9 syndrome and validation of Brighton criteria. Brain 137, 33\u201343 (2014).","journal-title":"Brain"},{"key":"BFnrneurol2014121_CR74","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1016\/j.vaccine.2011.01.007","volume":"29","author":"YJ Choe","year":"2011","unstructured":"Choe, Y. J., Cho, H., Bae, G. R., Lee, J. K. Guillain\u2013Barr\u00e9 syndrome following receipt of influenza A (H1N1) 2009 monovalent vaccine in Korea with an emphasis on Brighton Collaboration case definition. Vaccine 29, 2066\u20132070 (2011).","journal-title":"Vaccine"},{"key":"BFnrneurol2014121_CR75","doi-asserted-by":"publisher","first-page":"9697","DOI":"10.1016\/j.vaccine.2011.09.123","volume":"29","author":"FJ Mateen","year":"2011","unstructured":"Mateen, F. J.  et al. Guillain\u2013Barr\u00e9 syndrome in India: population-based validation of the Brighton criteria. Vaccine 29, 9697\u20139701 (2011).","journal-title":"Vaccine"},{"key":"BFnrneurol2014121_CR76","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1212\/WNL.48.2.328","volume":"48","author":"DE Moulin","year":"1997","unstructured":"Moulin, D. E., Hagen, N., Feasby, T. E., Amireh, R. & Hahn, A. Pain in Guillain\u2013Barr\u00e9 syndrome. Neurology 48, 328\u2013331 (1997).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR77","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1212\/WNL.0b013e3181f88345","volume":"75","author":"L Ruts","year":"2010","unstructured":"Ruts, L.  et al. Pain in Guillain\u2013Barr\u00e9 syndrome: a long-term follow-up study. Neurology 75, 1439\u20131447 (2010).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR78","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1136\/jnnp.51.5.605","volume":"51","author":"JB Winer","year":"1988","unstructured":"Winer, J. B., Hughes, R. A., Osmond, C. A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. J. Neurol. Neurosurg. Psychiatry 51, 605\u2013612 (1988).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2014121_CR79","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","volume":"363","author":"R van Koningsveld","year":"2004","unstructured":"van Koningsveld, R.  et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain\u2013Barr\u00e9 syndrome: randomised trial. Lancet 363, 192\u2013196 (2004).","journal-title":"Lancet"},{"key":"BFnrneurol2014121_CR80","doi-asserted-by":"crossref","unstructured":"[No authors listed] Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain\u2013Barr\u00e9 syndrome. Plasma Exchange\/Sandoglobulin Guillain\u2013Barr\u00e9 Syndrome Trial Group. Lancet 349, 225\u2013230 (1997).","DOI":"10.1016\/S0140-6736(96)09095-2"},{"key":"BFnrneurol2014121_CR81","first-page":"81","volume":"5","author":"M Samadi","year":"2013","unstructured":"Samadi, M., Kazemi, B., Golzari Oskoui, S. & Barzegar, M. Assessment of autonomic dysfunction in childhood Guillain\u2013Barr\u00e9 syndrome. J. Cardiovasc. Thorac. Res. 5, 81\u201385 (2013).","journal-title":"J. Cardiovasc. Thorac. Res."},{"key":"BFnrneurol2014121_CR82","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1001\/archneur.1992.00530300044009","volume":"49","author":"R Hughes","year":"1992","unstructured":"Hughes, R.  et al. Subacute idiopathic demyelinating polyradiculoneuropathy. Arch. Neurol. 49, 612\u2013616 (1992).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2014121_CR83","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1212\/WNL.51.6.1656","volume":"51","author":"S Kuwabara","year":"1998","unstructured":"Kuwabara, S.  et al. Two patterns of clinical recovery in Guillain\u2013Barr\u00e9 syndrome with IgG anti-GM1 antibody. Neurology 51, 1656\u20131660 (1998).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR84","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jneuroim.2010.09.017","volume":"231","author":"JB Winer","year":"2011","unstructured":"Winer, J. B. Guillain\u2013Barr\u00e9 syndrome: clinical variants and their pathogenesis. J. Neuroimmunol. 231, 70\u201372 (2011).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol2014121_CR85","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/jns5.12003","volume":"18","author":"J Drenthen","year":"2013","unstructured":"Drenthen, J.  et al. Limb motor nerve dysfunction in Miller Fisher syndrome. J. Peripher. Nerv. Syst. 18, 25\u201329 (2013).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"BFnrneurol2014121_CR86","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/jnnp-2013-305397","volume":"85","author":"BR Wakerley","year":"2014","unstructured":"Wakerley, B. R. & Yuki, N. Pharyngeal\u2013cervical\u2013brachial variant of Guillain\u2013Barr\u00e9 syndrome. J. Neurol. Neurosurg. Psychiatry 85, 339\u2013344 (2014).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2014121_CR87","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00415-011-6330-4","volume":"259","author":"N Yuki","year":"2012","unstructured":"Yuki, N.  et al. Guillain\u2013Barr\u00e9 syndrome associated with normal or exaggerated tendon reflexes. J. Neurol. 259, 1181\u20131190 (2012).","journal-title":"J. Neurol."},{"key":"BFnrneurol2014121_CR88","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.1016\/j.lpm.2013.02.328","volume":"42","author":"PA van Doorn","year":"2013","unstructured":"van Doorn, P. A. Diagnosis, treatment and prognosis of Guillain\u2013Barr\u00e9 syndrome (GBS). Presse Med. 42, e193\u2013e201 (2013).","journal-title":"Presse Med."},{"key":"BFnrneurol2014121_CR89","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1016\/j.clinph.2004.05.009","volume":"115","author":"S Vucic","year":"2004","unstructured":"Vucic, S., Cairns, K. D., Black, K. R., Chong, P. S. & Cros, D. Neurophysiologic findings in early acute inflammatory demyelinating polyradiculoneuropathy. Clin. Neurophysiol. 115, 2329\u20132335 (2004).","journal-title":"Clin. Neurophysiol."},{"key":"BFnrneurol2014121_CR90","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1212\/WNL.61.5.617","volume":"61","author":"M Capasso","year":"2003","unstructured":"Capasso, M.  et al. Acute motor conduction block neuropathy. Another Guillain\u2013Barr\u00e9 syndrome variant. Neurology 61, 617\u2013622 (2003).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR91","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/ana.410440210","volume":"44","author":"S Kuwabara","year":"1998","unstructured":"Kuwabara, S.  et al. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain\u2013Barr\u00e9 syndrome. Ann. Neurol. 44, 202\u2013208 (1998).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2014121_CR92","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/jnnp.2010.208538","volume":"81","author":"A Uncini","year":"2010","unstructured":"Uncini, A., Manzoli, C., Notturno, F., Capasso, M. Pitfalls in electrodiagnosis of Guillain\u2013Barr\u00e9 syndrome subtypes. J. Neurol. Neurosurg. Psychiatry 81, 1157\u20131163 (2010).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2014121_CR93","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1093\/brain\/awq260","volume":"133","author":"N Kokubun","year":"2010","unstructured":"Kokubun, N.  et al. Conduction block in acute motor axonal neuropathy. Brain 133, 2897\u20132908 (2010).","journal-title":"Brain"},{"key":"BFnrneurol2014121_CR94","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.clinph.2013.02.010","volume":"124","author":"N Kokubun","year":"2013","unstructured":"Kokubun, N., Shahrizaila, N., Koga, M., Hirata, K. & Yuki, N. The demyelination neurophysiological criteria can be misleading in Campylobacter jejuni-related Guillain\u2013Barr\u00e9 syndrome. Clin. Neurophysiol. 124, 1671\u20131679 (2013).","journal-title":"Clin. Neurophysiol."},{"key":"BFnrneurol2014121_CR95","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.clinph.2012.01.025","volume":"123","author":"A Uncini","year":"2012","unstructured":"Uncini, A. & Kuwabara, S. Electrodiagnostic criteria for Guillain\u2013Barr\u00e9 syndrome: a critical revision and the need for an update. Clin. Neurophysiol. 123, 1487\u20131495 (2012).","journal-title":"Clin. Neurophysiol."},{"key":"BFnrneurol2014121_CR96","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jns.2005.07.009","volume":"239","author":"ML Kuijf","year":"2005","unstructured":"Kuijf, M. L.  et al. Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA. J. Neurol. Sci. 239, 37\u201344 (2005).","journal-title":"J. Neurol. Sci."},{"key":"BFnrneurol2014121_CR97","first-page":"42","volume-title":"Guillain\u2013Barr\u00e9 Syndrome","author":"GJ Parry","year":"1993","unstructured":"Parry, G. J. Guillain\u2013Barr\u00e9 Syndrome 42\u201355 (Thieme Medical Publishers, 1993)."},{"key":"BFnrneurol2014121_CR98","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/978-1-4471-3175-5","volume-title":"Guillain\u2013Barr\u00e9 Syndrome","author":"RA Hughes","year":"1990","unstructured":"Hughes, R. A. Guillain\u2013Barr\u00e9 Syndrome 124\u2013130 (Springer-Verlag, 1990)."},{"key":"BFnrneurol2014121_CR99","first-page":"175","volume-title":"Guillain\u2013Barr\u00e9 Syndrome","author":"AH Ropper","year":"1991","unstructured":"Ropper, A. H., Wijdicks, E. F., Truax, B. T. Guillain\u2013Barr\u00e9 Syndrome 175\u2013224 (F. A. Davis, 1991)."},{"key":"BFnrneurol2014121_CR100","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1212\/WNL.47.3.813","volume":"47","author":"KC Gorson","year":"1996","unstructured":"Gorson, K. C., Ropper, A. H., Muriello, M. A. & Blair, R. Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain\u2013Barr\u00e9 syndrome. Neurology 47, 813\u2013817 (1996).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR101","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/mus.23749","volume":"48","author":"D Devos","year":"2013","unstructured":"Devos, D.  et al. Guillain\u2013Barr\u00e9 syndrome during childhood: particular clinical and electrophysiological features. Muscle Nerve 48, 247\u2013251 (2013).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol2014121_CR102","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1055\/s-2007-981686","volume":"38","author":"R Korinthenberg","year":"2007","unstructured":"Korinthenberg, R., Schessl, J. & Kirschner, J. Clinical presentation and course of childhood Guillain\u2013Barr\u00e9 syndrome: a prospective multicentre study. Neuropediatrics 38, 10\u201317 (2007).","journal-title":"Neuropediatrics"},{"key":"BFnrneurol2014121_CR103","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1212\/WNL.0b013e31820e7b62","volume":"76","author":"J Roodbol","year":"2011","unstructured":"Roodbol, J.  et al. Recognizing Guillain\u2013Barr\u00e9 syndrome in preschool children. Neurology 76, 807\u2013810 (2011).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR104","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1440-1754.2005.00602.x","volume":"41","author":"MM Ryan","year":"2005","unstructured":"Ryan, M. M. Guillain\u2013Barr\u00e9 syndrome in childhood. J. Paediatr. Child Health 41, 237\u2013241 (2005).","journal-title":"J. Paediatr. Child Health"},{"key":"BFnrneurol2014121_CR105","first-page":"A3808","volume":"155","author":"MC de Wit","year":"2011","unstructured":"de Wit, M. C., Roodbol, J., de Hoog, M., Catsman-Berrevoets, C. E. & Jacobs, B. C. Imminent respiratory insufficiency in children resulting from Guillain\u2013Barr\u00e9 syndrome [Dutch]. Ned. Tijdschr. Geneeskd. 155, A3808 (2011).","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"BFnrneurol2014121_CR106","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S0140-6736(78)92644-2","volume":"2","author":"RA Hughes","year":"1978","unstructured":"Hughes, R. A., Newsom-Davis, J. M., Perkin, G. D. & Pierce, J. M. Controlled trial prednisolone in acute polyneuropathy. Lancet 2, 750\u2013753 (1978).","journal-title":"Lancet"},{"key":"BFnrneurol2014121_CR107","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.nmd.2013.06.006","volume":"23","author":"EK Vanhoutte","year":"2013","unstructured":"Vanhoutte, E. K., Faber, C. G., Merkies, I. S. & PeriNomS study group. 196th ENMC international workshop: outcome measures in inflammatory peripheral neuropathies 8\u201310 February 2013, Naarden, The Netherlands. Neuromuscul. Disord. 23, 924\u2013933 (2013).","journal-title":"Neuromuscul. Disord."},{"key":"BFnrneurol2014121_CR108","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1212\/WNL.0b013e318208824b","volume":"76","author":"SI van Nes","year":"2011","unstructured":"van Nes, S. I.  et al. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology 76, 337\u2013345 (2011).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR109","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/mus.880141111","volume":"14","author":"RP Kleyweg","year":"1991","unstructured":"Kleyweg, R. P., van der Mech\u00e9, F. G. & Schmitz, P. I. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain\u2013Barr\u00e9 syndrome. Muscle Nerve 14, 1103\u20131109 (1991).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol2014121_CR110","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/brain\/awr318","volume":"135","author":"EK Vanhoutte","year":"2012","unstructured":"Vanhoutte, E. K.  et al. Modifying the Medical Research Council grading system through Rasch analyses. Brain 135, 1639\u20131649 (2012).","journal-title":"Brain"},{"key":"BFnrneurol2014121_CR111","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.pharmthera.2004.04.002","volume":"102","author":"MC Dalakas","year":"2004","unstructured":"Dalakas, M. C. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol. Ther. 102, 177\u2013193 (2004).","journal-title":"Pharmacol. Ther."},{"key":"BFnrneurol2014121_CR112","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1021\/pr401213z","volume":"13","author":"WJ Fokkink","year":"2014","unstructured":"Fokkink, W. J.  et al. IgG Fc N-glycosylation in Guillain\u2013Barr\u00e9 syndrome treated with immunoglobulins. J. Proteome Res. 13, 1722\u20131730 (2014).","journal-title":"J. Proteome Res."},{"key":"BFnrneurol2014121_CR113","doi-asserted-by":"crossref","unstructured":"[No authors listed] Plasmapheresis and acute Guillain\u2013Barr\u00e9 syndrome. The Guillain\u2013Barr\u00e9 syndrome Study Group. Neurology 35, 1096\u20131104 (1985).","DOI":"10.1212\/WNL.35.8.1096"},{"key":"BFnrneurol2014121_CR114","doi-asserted-by":"crossref","unstructured":"[No authors listed] Efficiency of plasma exchange in Guillain\u2013Barr\u00e9 syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain\u2013Barr\u00e9 syndrome. Ann. Neurol. 22, 753\u2013761 (1987).","DOI":"10.1002\/ana.410220612"},{"key":"BFnrneurol2014121_CR115","doi-asserted-by":"crossref","unstructured":"[No authors listed] Appropriate number of plasma exchanges in Guillain\u2013Barr\u00e9 syndrome. The French Cooperative Group on Plasma Exchange in Guillain\u2013Barr\u00e9 Syndrome. Ann. Neurol. 41, 298\u2013306 (1997).","DOI":"10.1002\/ana.410410304"},{"key":"BFnrneurol2014121_CR116","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","volume":"326","author":"FG van der Mech\u00e9","year":"1992","unstructured":"van der Mech\u00e9, F. G. & Schmitz, P. I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain\u2013Barr\u00e9 syndrome. Dutch Guillain\u2013Barr\u00e9 Study Group. N. Engl. J. Med. 326, 1123\u20131129 (1992).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol2014121_CR117","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1542\/peds.2004-1324","volume":"116","author":"R Korinthenberg","year":"2005","unstructured":"Korinthenberg, R., Schessl, J., Kirschner, J. & Monting, J. S. Intravenously administered immunoglobulin in the treatment of childhood Guillain\u2013Barr\u00e9 syndrome: a randomized trial. Pediatrics 116, 8\u201314 (2005).","journal-title":"Pediatrics"},{"key":"BFnrneurol2014121_CR118","first-page":"218","volume":"2","author":"MD Gajjar","year":"2013","unstructured":"Gajjar, M. D.  et al. Efficacy and cost effectiveness of therapeutic plasma exchange in patient of Guillain\u2013Barr\u00e9 syndrome\u2014a prospective study. Southeast Asian J. Case Rep. Rev. 2, 218\u2013228 (2013).","journal-title":"Southeast Asian J. Case Rep. Rev."},{"key":"BFnrneurol2014121_CR119","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/1472-6963-11-101","volume":"11","author":"JL Winters","year":"2011","unstructured":"Winters, J. L., Brown, D., Hazard, E., Chainani, A. & Andrzejewski, C. Jr. Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain\u2013Barr\u00e9 syndrome. BMC Health Serv. Res. 11, 101 (2011).","journal-title":"BMC Health Serv. Res."},{"key":"BFnrneurol2014121_CR120","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1526-0968.2004.00183.x","volume":"8","author":"MA Dada","year":"2004","unstructured":"Dada, M. A. & Kaplan, A. A. Plasmapheresis treatment in Guillain\u2013Barr\u00e9 syndrome: potential benefit over IVIg in patients with axonal involvement. Ther. Apher. Dial. 8, 409\u2013412 (2004).","journal-title":"Ther. Apher. Dial."},{"key":"BFnrneurol2014121_CR121","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1177\/08830738060210111201","volume":"21","author":"AK Baranwal","year":"2006","unstructured":"Baranwal, A. K., Ravi, R. N. & Singh, R. Exchange transfusion: a low-cost alternative for severe childhood Guillain\u2013Barr\u00e9 syndrome. J. Child Neurol. 21, 960\u2013965 (2006).","journal-title":"J. Child Neurol."},{"issue":"Suppl. 1","key":"BFnrneurol2014121_CR122","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.4103\/0972-2327.83087","volume":"14","author":"AK Meena","year":"2011","unstructured":"Meena, A. K., Khadilkar, S. V. & Murthy, J. M. Treatment guidelines for Guillain\u2013Barr\u00e9 syndrome. Ann. Indian Acad. Neurol. 14 (Suppl. 1), S73\u2013S81 (2011).","journal-title":"Ann. Indian Acad. Neurol."},{"key":"BFnrneurol2014121_CR123","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.jocn.2012.04.012","volume":"19","author":"AB Netto","year":"2012","unstructured":"Netto, A. B.  et al. A comparison of immunomodulation therapies in mechanically ventilated patients with Guillain Barr\u00e9 syndrome. J. Clin. Neurosci. 19, 1664\u20131667 (2012).","journal-title":"J. Clin. Neurosci."},{"key":"BFnrneurol2014121_CR124","first-page":"550","volume":"38","author":"J Tharakan","year":"1990","unstructured":"Tharakan, J., Jayaprakash, P. A. & Iyer, V. P. Small volume plasma exchange in Guillain\u2013Barr\u00e9 syndrome: experience in 25 patients. J. Assoc. Physicians India 38, 550\u2013553 (1990).","journal-title":"J. Assoc. Physicians India"},{"key":"BFnrneurol2014121_CR125","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1136\/jnnp.2006.102731","volume":"78","author":"MP Garssen","year":"2007","unstructured":"Garssen, M. P.  et al. Treatment of Guillain\u2013Barr\u00e9 syndrome with mycophenolate mofetil: a pilot study. J. Neurol. Neurosurg. Psychiatry 78, 1012\u20131013 (2007).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2014121_CR126","doi-asserted-by":"publisher","unstructured":"Overell, J. R., Hsieh, S. T., Odaka, M., Yuki, N. & Willison, H. J. Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD004761. http:\/\/dx.doi.org\/10.1002\/14651858.CD004761.pub2.","DOI":"10.1002\/14651858.CD004761.pub2"},{"key":"BFnrneurol2014121_CR127","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1212\/01.wnl.0000258673.31824.61","volume":"68","author":"M Mori","year":"2007","unstructured":"Mori, M., Kuwabara, S., Fukutake, T. & Hattori, T. Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology 68, 1144\u20131146 (2007).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR128","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1001\/archneur.62.8.1194","volume":"62","author":"RA Hughes","year":"2005","unstructured":"Hughes, R. A.  et al. Supportive care for patients with Guillain\u2013Barr\u00e9 syndrome. Arch. Neurol. 62, 1194\u20131198 (2005).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2014121_CR129","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s12028-011-9536-5","volume":"15","author":"ME Bos Eyssen","year":"2011","unstructured":"Bos Eyssen, M. E.  et al. Selective digestive tract decontamination decreases time on ventilator in Guillain\u2013Barr\u00e9 syndrome. Neurocrit. Care 15, 128\u2013133 (2011).","journal-title":"Neurocrit. Care"},{"key":"BFnrneurol2014121_CR130","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1212\/WNL.0b013e3181e07d14","volume":"74","author":"L Ruts","year":"2010","unstructured":"Ruts, L., Drenthen, J., Jacobs, B. C., van Doorn, P. A. & Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain\u2013Barr\u00e9 syndrome: a prospective study. Neurology 74, 1680\u20131686 (2010).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR131","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1136\/jnnp.54.11.957","volume":"54","author":"RP Kleyweg","year":"1991","unstructured":"Kleyweg, R. P. & van der Mech\u00e9, F. G. Treatment related fluctuations in Guillain\u2013Barr\u00e9 syndrome after high-dose immunoglobulins or plasma-exchange. J. Neurol. Neurosurg. Psychiatry 54, 957\u2013960 (1991).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2014121_CR132","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/mus.21480","volume":"41","author":"A Dionne","year":"2010","unstructured":"Dionne, A., Nicolle, M. W. & Hahn, A. F. Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy. Muscle Nerve 41, 202\u2013207 (2010).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol2014121_CR133","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1212\/WNL.53.2.409","volume":"53","author":"RA Bernsen","year":"1999","unstructured":"Bernsen, R. A., de Jager, A. E., Schmitz, P. I. & van der Mech\u00e9, F. G. Residual physical outcome and daily living 3 to 6 years after Guillain\u2013Barr\u00e9 syndrome. Neurology 53, 409\u2013410 (1999).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR134","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1136\/jnnp.62.6.637","volume":"62","author":"RA Bernsen","year":"1997","unstructured":"Bernsen, R. A., Jacobs, H. M., de Jager, A. E. & van der Mech\u00e9, F. G. Residual health status after Guillain\u2013Barr\u00e9 syndrome. J. Neurol. Neurosurg. Psychiatry 62, 637\u2013640 (1997).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2014121_CR135","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s00415-005-0958-x","volume":"253","author":"A Bersano","year":"2006","unstructured":"Bersano, A.  et al. Long term disability and social status change after Guillain\u2013Barr\u00e9 syndrome. J. Neurol. 253, 214\u2013218 (2006).","journal-title":"J. Neurol."},{"key":"BFnrneurol2014121_CR136","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1212\/01.WNL.0000148589.87107.9C","volume":"63","author":"MP Garssen","year":"2004","unstructured":"Garssen, M. P.  et al. Physical training and fatigue, fitness, and quality of life in Guillain\u2013Barr\u00e9 syndrome and CIDP. Neurology 63, 2393\u20132395 (2004).","journal-title":"Neurology"},{"issue":"Suppl. 3","key":"BFnrneurol2014121_CR137","doi-asserted-by":"publisher","first-page":"S203","DOI":"10.1016\/j.nmd.2012.10.014","volume":"22","author":"IS Merkies","year":"2012","unstructured":"Merkies, I. S. & Faber, C. G. Fatigue in immune-mediated neuropathies. Neuromuscul. Disord. 22 (Suppl. 3), S203\u2013S207 (2012).","journal-title":"Neuromuscul. Disord."},{"key":"BFnrneurol2014121_CR138","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1212\/WNL.53.8.1648","volume":"53","author":"IS Merkies","year":"1999","unstructured":"Merkies, I. S., Schmitz, P. I., Samijn, J. P., van der Mech\u00e9, F. G. & van Doorn, P. A. Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 53, 1648\u20131654 (1999).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR139","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1212\/01.WNL.0000149521.65474.83","volume":"64","author":"C Dornonville de la Cour","year":"2005","unstructured":"Dornonville de la Cour, C. & Jakobsen, J. Residual neuropathy in long-term population-based follow-up of Guillain\u2013Barr\u00e9 syndrome. Neurology 64, 246\u2013253 (2005).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR140","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jns.2007.08.005","volume":"264","author":"R Dhar","year":"2008","unstructured":"Dhar, R., Stitt, L. & Hahn, A. F. The morbidity and outcome of patients with Guillain\u2013Barr\u00e9 syndrome admitted to the intensive care unit. J. Neurol. Sci. 264, 121\u2013128 (2008).","journal-title":"J. Neurol. Sci."},{"key":"BFnrneurol2014121_CR141","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1212\/WNL.54.12.2311","volume":"54","author":"DD Fletcher","year":"2000","unstructured":"Fletcher, D. D., Lawn, N. D., Wolter, T. D. & Wijdicks, E. F. Long-term outcome in patients with Guillain\u2013Barr\u00e9 syndrome requiring mechanical ventilation. Neurology 54, 2311\u20132315 (2000).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR142","first-page":"507","volume":"48","author":"F Khan","year":"2012","unstructured":"Khan, F. & Amatya, B. Rehabilitation interventions in patients with acute demyelinating inflammatory polyneuropathy: a systematic review. Eur. J. Phys. Rehabil. Med. 48, 507\u2013522 (2012).","journal-title":"Eur. J. Phys. Rehabil. Med."},{"key":"BFnrneurol2014121_CR143","doi-asserted-by":"publisher","first-page":"638","DOI":"10.2340\/16501977-0826","volume":"43","author":"F Khan","year":"2011","unstructured":"Khan, F.  et al. Outcomes of high- and low-intensity rehabilitation programme for persons in chronic phase after Guillain\u2013Barr\u00e9 syndrome: a randomized controlled trial. J. Rehabil. Med. 43, 638\u2013646 (2011).","journal-title":"J. Rehabil. Med."},{"key":"BFnrneurol2014121_CR144","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1529-8027.2009.00238.x","volume":"14","author":"SI van Nes","year":"2009","unstructured":"van Nes, S. I.  et al. Improving fatigue assessment in immune-mediated neuropathies: the modified Rasch-built fatigue severity scale. J. Peripher. Nerv. Syst. 14, 268\u2013278 (2009).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"BFnrneurol2014121_CR145","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1212\/01.wnl.0000436073.21406.e6","volume":"81","author":"J Drenthen","year":"2013","unstructured":"Drenthen, J.  et al. Residual fatigue in Guillain\u2013Barr\u00e9 syndrome is related to axonal loss. Neurology 81, 1827\u20131831 (2013).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR146","doi-asserted-by":"publisher","unstructured":"Liu, J., Wang, L. N. & McNicol, E. D. Pharmacological treatment for pain in Guillain\u2013Barr\u00e9 syndrome. Cochrane Database of Systematic Reviews, Issue 10. Art. No.: CD009950. http:\/\/dx.doi.org\/10.1002\/14651858.CD009950.pub2.","DOI":"10.1002\/14651858.CD009950.pub2"},{"key":"BFnrneurol2014121_CR147","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1212\/WNL.0b013e3181f88393","volume":"75","author":"KC Gorson","year":"2010","unstructured":"Gorson, K. C. This disorder has some nerve: chronic pain in Guillain\u2013Barr\u00e9 syndrome. Neurology 75, 1406\u20131407 (2010).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR148","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/brain\/awg039","volume":"126","author":"CL Pan","year":"2003","unstructured":"Pan, C. L.  et al. Cutaneous innervation in Guillain\u2013Barr\u00e9 syndrome: pathology and clinical correlations. Brain 126, 386\u2013397 (2003).","journal-title":"Brain"},{"key":"BFnrneurol2014121_CR149","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.pain.2011.10.037","volume":"153","author":"L Ruts","year":"2012","unstructured":"Ruts, L.  et al. Unmyelinated and myelinated skin nerve damage in Guillain\u2013Barr\u00e9 syndrome: correlation with pain and recovery. Pain 153, 399\u2013409 (2012).","journal-title":"Pain"},{"key":"BFnrneurol2014121_CR150","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/jns5.12050","volume":"19","author":"J Kalita","year":"2014","unstructured":"Kalita, J., Misra, U. K., Goyal, G. & Das, M. Guillain\u2013Barr\u00e9 syndrome: subtypes and predictors of outcome from India. J. Peripher. Nerv. Syst. 19, 36\u201343 (2014).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"BFnrneurol2014121_CR151","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jns.2013.11.016","volume":"337","author":"M Samukawa","year":"2014","unstructured":"Samukawa, M.  et al. Clinical features in Guillain\u2013Barr\u00e9 syndrome with anti-Gal-C antibody. J. Neurol. Sci. 337, 55\u201360 (2014).","journal-title":"J. Neurol. Sci."},{"key":"BFnrneurol2014121_CR152","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/mus.880171004","volume":"17","author":"DW Zochodne","year":"1994","unstructured":"Zochodne, D. W. Autonomic involvement in Guillain\u2013Barr\u00e9 syndrome: a review. Muscle Nerve 17, 1145\u20131155 (1994).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol2014121_CR153","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1097\/00003246-200301000-00044","volume":"31","author":"T Sharshar","year":"2003","unstructured":"Sharshar, T., Chevret, S., Bourdain, F., Rapha\u00ebl, J. C. & French Cooperative Group on Plasma Exchange in Guillain\u2013Barr\u00e9 Syndrome. Early predictors of mechanical ventilation in Guillain\u2013Barr\u00e9 syndrome. Crit. Care Med. 31, 278\u2013283 (2003).","journal-title":"Crit. Care Med."},{"key":"BFnrneurol2014121_CR154","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S1474-4422(06)70603-2","volume":"5","author":"MC Durand","year":"2006","unstructured":"Durand, M. C.  et al. Clinical and electrophysiological predictors of respiratory failure in Guillain\u2013Barr\u00e9 syndrome: a prospective study. Lancet Neurol. 5, 1021\u20131028 (2006).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2014121_CR155","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ana.21976","volume":"67","author":"C Walgaard","year":"2010","unstructured":"Walgaard, C.  et al. Prediction of respiratory insufficiency in Guillain\u2013Barr\u00e9 syndrome. Ann. Neurol. 67, 781\u2013787 (2010).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2014121_CR156","unstructured":"IGOS GBS prognosis tool. IGOS International GBS Outcome Study [online], (2014)."},{"key":"BFnrneurol2014121_CR157","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1212\/01.WNL.0000035640.84053.5B","volume":"60","author":"RD Henderson","year":"2003","unstructured":"Henderson, R. D., Lawn, N. D., Fletcher, D. D., McClelland, R. L. & Wijdicks, E. F. The morbidity of Guillain\u2013Barr\u00e9 syndrome admitted to the intensive care unit. Neurology 60, 17\u201321 (2003).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR158","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1385\/NCC:5:3:230","volume":"5","author":"TN Nguyen","year":"2006","unstructured":"Nguyen, T. N.  et al. Factors predicting extubation success in patients with Guillain\u2013Barr\u00e9 syndrome. Neurocrit. Care 5, 230\u2013234 (2006).","journal-title":"Neurocrit. Care"},{"key":"BFnrneurol2014121_CR159","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/(SICI)1097-4598(199908)22:8<1058::AID-MUS8>3.0.CO;2-G","volume":"22","author":"ND Lawn","year":"1999","unstructured":"Lawn, N. D. & Wijdicks, E. F. Tracheostomy in Guillain\u2013Barr\u00e9 syndrome. Muscle Nerve 22, 1058\u20131062 (1999).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol2014121_CR160","doi-asserted-by":"crossref","unstructured":"[No authors listed] The prognosis and main prognostic indicators of Guillain\u2013Barr\u00e9 syndrome. A multicentre prospective study of 297 patients. The Italian Guillain\u2013Barr\u00e9 Study Group. Brain 119, 2053\u20132061 (1996).","DOI":"10.1093\/brain\/119.6.2053"},{"key":"BFnrneurol2014121_CR161","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/jca.10066","volume":"18","author":"BC Cheng","year":"2003","unstructured":"Cheng, B. C.  et al. Long-term prognosis for Guillain\u2013Barr\u00e9 syndrome: evaluation of prognostic factors and clinical experience of automated double filtration plasmapheresis. J. Clin. Apher. 18, 175\u2013180 (2003).","journal-title":"J. Clin. Apher."},{"key":"BFnrneurol2014121_CR162","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1212\/01.WNL.0000055091.96905.D0","volume":"60","author":"A Chio","year":"2003","unstructured":"Chio, A.  et al. Guillain\u2013Barr\u00e9 syndrome: a prospective, population-based incidence and outcome survey. Neurology 60, 1146\u20131150 (2003).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR163","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S1474-4422(07)70130-8","volume":"6","author":"R van Koningsveld","year":"2007","unstructured":"van Koningsveld, R.  et al. A clinical prognostic scoring system for Guillain\u2013Barr\u00e9 syndrome. Lancet Neurol. 6, 589\u2013594 (2007).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2014121_CR164","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1212\/WNL.53.3.598","volume":"53","author":"LH Visser","year":"1999","unstructured":"Visser, L. H., Schmitz, P. I., Meulstee, J., van Doorn, P. A. & van der Mech\u00e9, F. G. Prognostic factors of Guillain\u2013Barr\u00e9 syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain\u2013Barr\u00e9 Study Group. Neurology 53, 598\u2013604 (1999).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR165","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1056\/NEJM199511233332102","volume":"333","author":"JH Rees","year":"1995","unstructured":"Rees, J. H., Soudain, S. E., Gregson, N. A. & Hughes, R. A. Campylobacter jejuni infection and Guillain\u2013Barr\u00e9 syndrome. N. Engl. J. Med. 333, 1374\u20131379 (1995).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol2014121_CR166","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1212\/WNL.0b013e3182104407","volume":"76","author":"C Walgaard","year":"2011","unstructured":"Walgaard, C.  et al. Early recognition of poor prognosis in Guillain\u2013Barr\u00e9 syndrome. Neurology 76, 968\u2013975 (2011).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR167","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/ana.410230407","volume":"23","author":"DR Cornblath","year":"1988","unstructured":"Cornblath, D. R.  et al. Motor conduction studies in Guillain\u2013Barr\u00e9 syndrome: description and prognostic value. Ann. Neurol. 23, 354\u2013359 (1988).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2014121_CR168","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1136\/jnnp.70.4.560","volume":"70","author":"S Kuwabara","year":"2001","unstructured":"Kuwabara, S., Mori, M., Ogawara, K., Hattori, T. & Yuki, N. Indicators of rapid clinical recovery in Guillain\u2013Barr\u00e9 syndrome. J. Neurol. Neurosurg. Psychiatry 70, 560\u2013562 (2001).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2014121_CR169","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1212\/01.wnl.0000310983.38724.d4","volume":"70","author":"A Alshekhlee","year":"2008","unstructured":"Alshekhlee, A., Hussain, Z., Sultan, B. & Katirji, B. Guillain\u2013Barr\u00e9 syndrome: incidence and mortality rates in US hospitals. Neurology 70, 1608\u20131613 (2008).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR170","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1212\/WNL.0b013e3182904fcc","volume":"80","author":"B van den Berg","year":"2013","unstructured":"van den Berg, B., Bunschoten, C., van Doorn, P. A. & Jacobs, B. C. Mortality in Guillain\u2013Barr\u00e9 syndrome. Neurology 80, 1650\u20131654 (2013).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR171","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1212\/WNL.52.3.635","volume":"52","author":"ND Lawn","year":"1999","unstructured":"Lawn, N. D. & Wijdicks, E. F. Fatal Guillain\u2013Barr\u00e9 syndrome. Neurology 52, 635\u2013638 (1999).","journal-title":"Neurology"},{"key":"BFnrneurol2014121_CR172","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online], (2014)."},{"key":"BFnrneurol2014121_CR173","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1113\/jphysiol.2009.171702","volume":"587","author":"JJ Plomp","year":"2009","unstructured":"Plomp, J. J. & Willison, H. J. Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction. J. Physiol. 587, 3979\u20133999 (2009).","journal-title":"J. Physiol."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2014.121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2014.121","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2014.121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T17:22:08Z","timestamp":1733937728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2014.121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,15]]},"references-count":173,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["BFnrneurol2014121"],"URL":"https:\/\/doi.org\/10.1038\/nrneurol.2014.121","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,15]]},"assertion":[{"value":"15 July 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.C.J. receives research support from the Netherlands Organization for Health Research and Development, Erasmus MC, Prinses Beatrix Spierfonds and the Guillain\u2013Barr\u00e9 syndrome, chronic inflammatory demyelinating polyneuropathy (GBS\u2013CIDP) Foundation International, and travel support from Baxter Biopharmaceutics. P.A.v.D. receives research support from the Prinses Beatrix Spierfonds, the GBS-CIDP Foundation International, Baxter Biopharmaceutics, Griffols and Sanquin Plasma Products. B.v.d.B., C.W., J.D. and C.F. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}